- LOGIN
- MemberShip
- 2026-05-21 00:37:37
- Company
- Collapse of Cialis, 6th place in 4 years
- by An, Kyung-Jin Dec 16, 2019 06:21am
- (Clockwise from top left) Photographs of Cendom, Viagra, Palpal, Cialis The market position of Cialis, which squeezed the market for erectile dysfunction with Viagra, was greatly reduced. In the aftermath of the generic drug market by domestic pharmaceutical companies, sales shrank to one-third of patent expiration. The share rank has changed from 1st to 6th place four years ago. Generic products such as 'Palpal' and 'Cendom' continued to strengthen in the entire erectile dysfunction treatment market. According to IQVIA data on the 11th, the market for erectile dysfunction drugs in the third quarter was ￦28.3 billion, an increase of 8.3% compared to the previous year. This is an increase of 13.8% from ￦25.3 billion in the third quarter 2015. Quarterly market size is steadily rising as generic products launched by domestic pharmaceutical companies are growing. Quarterly Sales of Major Erectile Dysfunction Therapeutics (Unit: KRW million, Source: IQVIA) In terms of sales of erectile dysfunction treatment, Hanmi Pharmaceutical's 'Palpal' has firmly maintained its leading position for four years since 2016. Palpal is a generic product of Viagra (Sildenafil) released in 2012. Palpal sold ￦5.7 billion in the third quarter, accounting for 20.1% of the market for erectile dysfunction. The company's sales grew 10.6% YoY to ￦5.2 billion, maintaining a more than double gap with its second-place Cendom. Palpal, which made an entry mark in the erectile dysfunction treatment market immediately after its patent expiration, exceeded sales of Viagra, the same ingredient as its original product, within a year after its release. In the fourth quarter of 2015, even the original Cialis, which was Tadalafil-based, beat the original erectile dysfunction treatment throne. Since then, it has not missed a market leader. Strong accent for generics were even more pronounced in the Tadalafil market. Chong Kun Dang's 'Cendom' remained second in sales, selling ￦2.5 billion in the third quarter. The company's market share increased to 8.8%, recording a 6.3% year-on-year growth. Cendom is a generic product that was released after the Cialis (Tadalafil) patent expired in September 2015. Since its launch, its market share has gradually increased, surpassing the original Cialis in the fourth quarter of 2017. In the fourth quarter of last year, the company is chasing Palpal by exceeding Viagra sales. Gugu by Hanmi, Another generic product of Tadalafil, ranked fourth overall in the third quarter, selling ￦1.8 billion, a 6.3% increase from the previous year. Original pharmaceuticals from multinational pharmaceuticals showed a sharp decline. Cialis sales in Lilly Korea fell 13.6% YoY to ￦1.5 billion. Compared to ￦5.1 billion in the third quarter of 2015, two-thirds of sales evaporated. At the same time as Cialis expired, it gave Palpal by Hanmi Pharmaceuticals a leading position in sales of erectile dysfunction drugs in Korea. Since then, The sales have been sequentially overtaken by Pfizer Viagra and Chong Kun Dang Cendom. Lilly signed a contract with Handok, a former sales partner, last year Lilly took complete charge of Cialis' domestic distribution, marketing and sales activities. However, there was no sales rebound effect. Cialis was pushed down to the same ingredient generic product, Gugu, in the second quarter of this year, and was lower than SK Chemical's 'MvixS' (Mirodenafil). After four years of patent expiry, the sales ranking has fallen by five steps. The gap with Dong-A 'Zydena (Udenafil), which ranked seventh in the third quarters, is only ￦10 million. Pfizer's Viagra sales are unlikely to recover. Viagra's third quarter sales came in at ￦2.4 billion, similar to the same period last year. The domestic market for erectile dysfunction drugs is estimated at 8.4%. It was once called the pronoun for erectile dysfunction, but its current sales are less than half of its Palpal. Comparison of 2018-2019 3Q revenue of major erectile dysfunction treatments (Unit:￦1million, %, Source: IQVIA)
- Company
- Industry feels growing pressure on metformin risk
- by Chon, Seung-Hyun Dec 16, 2019 06:21am
- Ministry of Food and Drug Safety (MFDS) The pharmaceutical industry’s concern over metformin impurity contamination is growing. The industry’s eyes are focused on the government’s action following its ongoing metformin usage status review. Some of pharmaceutical companies are promptly equipping themselves with impurity analyzer a self-testing. ◆MFDS initiates metformin usage status review, the industry fears of follow-up action An industry source reported on Dec. 15 that Korea’s Ministry of Food and Drug Safety (MFDS) has ordered pharmaceutical companies to assess manufacturing record of pharmaceutical product containing ‘metformin hydrochloride’ and investigate used active pharmaceutical ingredient. MFDS asked companies to report total number of drug items consisting of metformin substance, names and number of manufactured items, and names and number of non-manufactured items until Dec. 17. Molecular structure of metformin Pharmaceutical companies have to provide all information of items even covering ones in distribution at the moment, considering use-by date of complete products. For example, when an items’ use-by date is three years, then the item’s entire manufacturing record after December 2016 should be looked into. The ministry is also calling for a full report on active ingredients used in the metformin products. It means the ministry means to collect detailed information on DMF registration number and manufacturing plant of a complete product containing the ingredient under each serial number. The procedure resembles the ranitidine and nizatidine cases. When they find an issue in specific active ingredient and complete drug, the ministry can take a fast and accurate action based on the information submitted by companies. The pharmaceutical industry predicts the government direction is a part of the ministry’s preparation process, in case impurity is discovered in metformin medicine. Before the government body took an action on ranitidine and nizatidine cases, the ministry had reviewed detailed information on complete product and the active ingredients. MFDS had immediately ordered a sales ban on drugs with valsartan when Europe decided to recall the products, but it held back on the action for ranitidine and nizatidine until the thorough review on complete products and the ingredients was completed. The risk of metformin impurity broke out from Singapore. On Dec. 4, Singapore’s Health Sciences Authority (HSA) recalled three items out of 46 metformin containing drugs they investigated. The result confirmed contamination of N-Nitrosodimethylamine (NDMA) has surpassed daily acceptable level. Since then, the U.S., Europe and Japan initiated impurity testing on metformin drugs. All three regions are recommending companies to conduct self-testing on NDMA levels in their metformin drugs. ◆Companies initiating impurity self-tests and purchasing analyzer Companies in Korea are also encouraged to run self-tests on their metformin-containing items. So far the ministry has not officially instructed companies to test impurity in metformin ingredients. In fact, the ministry has not even ordered them to test NDMA level in complete product or announced a plan to collect all items for further investigation. MFDS’ lack of instruction could be because of the U.S. and Europe have not ordered for a recall on products with alarming impurity level, and also because the problematic metformin ingredient and complete product with the ingredient have not even been imported to Korea. Moreover, there has not been an official procedure of NDMA testing presented by the ministry. The complete products with contaminated metformin recalled in Singapore have not been imported to Korea, yet. However, it has not been confirmed yet if the active ingredient used in the recalled product has been used in Korea. Apparently, the Singaporean regulator has decided to recall the products after testing complete products, not the active ingredient. The pharmaceutical companies in Korea have no other choice, but to test their metformin products according to the active pharmaceutical ingredient impurity risk management measure the ministry has unveiled recently. While announcing the investigation result of nizatidine contamination last month, MFDS ordered companies to conduct a self-test on all of their synthetic active ingredients for impurity like NDMA. Accordingly, synthetic ingredient manufacturer and importer, as well as complete product companies, have to evaluate contamination risk in drugs either during manufacturing or storing processes. Pharmaceutical impurity risk management initiative unveiled by MFDS last month Moreover, pharmaceutical companies have to immediately report any discovery of impurity to MFDS after conducting self-evaluation on suspected items with risk of NDMA-like impurity contamination. Basically, metformin became the first substance to be ‘suspected for contamination risk’ since the ministry’s impurity risk management initiative. The industry seems to be in process of attempting self-analyze NDMA level in metformin medicine. However, the testing process has not been so simple without an official testing procedure and lack of laboratories with proper analysis equipment. Currently, only nizatidine-containing products verified with approved level of NDMA can be distributed, but the testing laboratories are unable deliver testing results in requested time as they are backed-up with all companies with nizatidine products. MFDS has ordered pharmaceutical companies to supply nizatidine-containing item with passing level of cancer-causing NDMA contamination (less than 0.32ppm), verified by testing done for each item serial number. The test can be done by Korean Good Manufacturing Practice (GMP) certified manufacturer, MFDS designated quality test institute, city and provincial-managed environment research lab and Korean Pharmaceutical Traders Association. MFDS ordered pharmaceutical companies to test NDMA level in nizatidine medicine before supplying Some of pharmaceutical companies are even considering on purchasing testing equipment to run it by themselves. But an analyzer costing up to 300 million to 500 million won, beside the six-figure annual maintenance, cost is definitely putting a strain on the company. A pharmaceutical company insider commented, “The company is taking account of equipping impurity risk examination system as its own quality management program. We are also discussing possibility of sharing an ownership and purchase cost of the analyzer”.
- Policy
- Exclusivity for Galvus’ generics applied Aug 2021
- by Lee, Tak-Sun Dec 13, 2019 11:00pm
- Galvus by NovartisAs expected, Ahn-Gook Pharmaceutical obtained the approval for exclusivity for generic product as Galvus (Vildagliptin), a diabetes treatment of DPP-4. The MFDS designated the priority sale items for Ahn-Gook Vildagliptin Tablet 50mg of Ahn-Gook Pharmaceutical and Ahn-Gook Newpharrm Vilagliptin Tablet 50mg of its subsidiary Ahn-Gook Newpharm. As a result, it is not possible to sell any of the late-release drugs, except for Ahn-gook Pharm., From August 30 2021 to May 29 2022. Ahn-Gook Pharmaceuticals first filed a trial for extended period of invalidity on Galvus' patent for the first time as a domestic company on July 14 2017. This succeeded in invalidating the extended duration 187 of the material patent. The company received the affirmed decision. It is the first generic item to submit a permit application in last March. The company obtained a product license last month. Three conditions required for the right of exclusivity for generic product : the first patent challenge, the successful patent challenge, and the first application for permission and The company achieved all 3 conditions perfectly. The ban on late drug sales from August 30 2021. This is because Ahn-Gook advanced 187 during Galvus' patent expiration date, which is expected to expire on March 4, 2022 On the other hand, late-runners outside of Ahn-Gook are trying to circumvent the sale ban by Ahn-Gook’s right of exclusivity for generic product. Hanmi pharmaceticals has a strong chance of obtaining a separate right to sell salt-modified drugs and is currently applying for a permit. Korea United Pharm Inc , Kolmar Korea, and Alvogen Korea have also begun developing late-on drugs.
- Company
- Bayer Korea appoints Freda Lin as a new President
- by Eo, Yun-Ho Dec 13, 2019 10:59pm
- 프레다 린 대표 Bayer Korea has announced an appointment of Freda Ta-Ling Lin as a new President , starting from Jan. 1, 2020. The Korean branch’s top executive position has been vacant since the former President Ingrid Drechsel transferred to Bayer’s Turkish branch. From October, Bayer Korea’s Pharmaceuticals division has been managed by Lee Jina, a head of Cardiovascular Therapeutics Area. New President Freda Lin is a seasoned global leader in sales and marketing with 25 years of vast experience in the pharmaceutical industry. From 2013 to recent, Lin has been leading Bayer Taiwan as a head of Pharmaceuticals division and a President of the region. Previously, Lin has been building her career in the pharmaceutical industry as sales, market and strategic planning executive at GlaxoSmithKline’s Taiwan, China, Asia Pacific, and the U.K. branches. Moreover, Freda Lin is also to simultaneously serve as a head of Pharmaceuticals Division at Bayer Korea. New President Freda Lin said, “I am pleased to serve the role of President and to lead Bayer Korea in a country considered as one of the most innovative countries in the world”.
- Company
- Boryung Holdings appoints Kim Jung Gyun as New CEO
- by Eo, Yun-Ho Dec 13, 2019 10:59pm
- CEO Kim Jung Gyun Boryung Holdings recently convened a board meeting and appointed Chief Operating Officer Kim Jung Gyun as the new Chief Executive Officer. Joined Boryung Pharmaceutical in 2014 as a director, the new CEO Kim Jung Gyun served in Strategic Planning team, Production Management team, Human Resources team and was appointed as an executive director and COO at Boryung Holdings in January 2017. CEO Kim has contributed in increasing sales and improving profitability at Boryung Pharmaceutical by endeavoring on initiatives like ‘internal operational management system,’ ‘investment reprioritization,’ ‘generating open innovation-based new business like Vigen Cell’, and ‘building transparent and horizontal organizational culture’. As the COO of Boryung Holdings, Kim started establishing a holding company and subsidiary ‘Boryung Consumer’ since 2017, and shifted each business division to center board members for set a faster and transparent decision making process. Moreover, Kim reinforced collaboration system between board member executives to expand corporate value. Undergoing a series of changes, Boryung Pharmaceutical’s compound annual growth rate marked 7.1 percent in last three years, and its profitability has been significantly improved. The company is expected to make a record-high sales and operating profit this year. Besides, a vaccine manufacturer and biopharmaceutical R&D affiliate ‘Boryung Biopharma’ has also shown a steep growth and is expected to generate 100 billion won in 2019. CEO Kim stated, “As Korea is a part of top global markets, we should be the fastest to adapt to changes happening outside, constantly seek for opportunity in the global market, and invest on opportunity in future digital healthcare industry consisting of pharmaceutical industry, IT technology and healthcare”. Meanwhile, the current CEO of Boryung Pharmaceutical Ahn Jae-hyun resigned from his other position as a CEO of Boryung Holdings.
- Company
- MFDS to wait and see self-test results on metformin
- by Chon, Seung-Hyun Dec 13, 2019 06:34am
- Ministry of Food and Drug Safety (MFDS) The government seems to have decided to encourage pharmaceutical companies to run their own impurity contamination test on metformin drugs. Unlike the ranitidine and nizatidine incidents, the government means to wait and see the companies’ self-investigation results, rather than to take an action by itself. Basically, metformin would be the first substance to be applied with the recently unveiled impurity risk management initiative. However, the possibility still exists for the government to immediately call for sales ban and other follw-up measures, when a exceeding level of impurity is found in a product, either in Korea or overseas. According to the industry source on Dec. 12, Korea’s Ministry of Food and Drug Safety (MFDS) has not made any official order to pharmaceutical companies regarding findings of cancer-causing impurity in metformin. On Dec. 4, Singapore’s Health Science Authority (HSA) has decided to recall three out of 46 metformin products tested. Apparently, the regulator found N-nitrosodimenthylamin (NDMA) exceeding an acceptable level of daily consumption in metformin products. Since then, the U.S. and European health regulators have also started probing on contaminated metformin products. The U.S. Food and Drug Administration (FDA) is reportedly investigating NDMA discovered in metformin products available in the U.S. It also stated it would recommend recalling products with exceeding levels of NDMA contamination. The European Medicines Agency (EMA) has ordered companies to conduct NDMA contamination testing. Japan’s Ministry of Health, Labor and Welfare recently ordered metformin containing product manufacturers and importers in Japan to analyze and report risk of NDMA contamination in the substance and complete products. So far, MFDS has only stated it would “review investigation results”, and no other specific orders have not been given to the companies. The ministry has not yet ordered the companies to investigate NDMA in metformin active agent or complete product, nor has it stated the ministry would directly collect and investigate the substance. The ministry’s reaction is contrasting from the follow-up measures it had with other pharmaceutical impurity risk incidents. When the European regulator announced it would recall all valsartan products, the Korean ministry immediately banned sales of products with the same active ingredient. And after the sales ban was ordered in the U.S., the ministry once said “nothing to worry about”, but soon after it ordered an all-product ban. Actions on nizatidine followed the ranitidine sales ban. After collecting and testing active ingredient and complete product with similar chemical structure as ranitidine, MFDS banned sales on 13 items with unacceptable level of NDMA. It could be interpreted that the authority is trying to encourage companies to voluntarily test their metformin products. Neither of the U.S. or Europe has called for a recall due to exceeding level of the contamination. And the complete products reported with the impurity to date are not available in Korea, yet. MFDS official explained, “We have already asked companies to test the impurity in all products themselves”. It also means the recently introduced active ingredient impurity risk management initiative would be applied on metformin. In fact, MFDS has already asked pharmaceutical companies to run NDMA-like impurity test on all synthetic active agents, when announcing the investigation result of nizatidine medicine. Accordingly, synthetic ingredient manufacturer and importers, as well as complete product companies, have to evaluate risk of impurity contaminated during the process of manufacturing or storing. Pharmaceutical companies suspecting a risk of discovering NDMA and other harmful impurity in their product should immediately conduct a voluntary test and has to report MFDS as soon as possible when it is actually found. The impurity risk evaluation and testing should be conducted voluntarily, and the result of risk evaluation should reported by May 2020, and the result of test by May 2021. Pharmaceutical impurity risk management initiative presented by MFDS last month Since MFDS has introduced the impurity management initiative, metformin basically became the first case of ‘medicine with high risk’. In other words, MFDS is unlikely to test metformin itself, as of now. Moreover, metformin being a commonly used agent seems to make MFDS hesitant about testing the products proactively. Metformin is the most commonly prescribed first-line treatment for patients with Type 2 diabetes to control glucose level. In Korea alone, 642 of approved complete products contain metformin. Practically, all pharmaceutical companies have at least one metformin medicine. Compared to valsartan and ranitidine market, metformin has a far larger market volume. Pharmaceutical industry research firm UBIST reported outpatient prescription market volume of metformin product reached 420 billion won last year. It soared 63.4 percent in four years from 257.1 billion won in 2014. Currently banned ranitidine products generated about 200 billion won as outpatient prescription, but metformin market easily doubles the ranitidine market. A single dose of metformin is priced at less than a hundred one with reimbursement. Considering the pricing, metformin’s usage volume is overwhelmingly bigger than ranitidine. Yearly trend of outpatient prescription volume of metformin product (unit: KRW 100 million) Source: UBIST If the testing confirms metformin is contaminated with NDMA during the process of storing, active agent and complete product should be reviewed by each serial number. In such case, millions of serialized products would have to be investigated. It is physically impossible for MFDS to directly investigate them all. However, the ministry may initiate a full investigation, depending on the updates from home and abroad. The ministry’s hands-on investigation would be inevitable when active ingredient or complete product in Korea is found with exceeding level of impurity is reported from overseas. And even when a Korean company reports any case of NDMA contamination exceeding an acceptable level, full investigation is likely follow.
- Policy
- Galvus SR developed by Alvogen, 100mg once daily
- by Lee, Tak-Sun Dec 13, 2019 06:34am
- Galvus by NovartisAlvogen Korea is trying to differentiate itself from domestic competitors by developing Galvus SR tablets. The drug Alvogen develops is a sustained-release multi-layered tablet containing Vilagliptin, which is known to be taken once a day, unlike the original. The MFDS approved Alvogen Vildagliptin SR tablet’s clinical protocols on the 27th of last month. It proceeds to compare the pharmacokinetics and safety of the original drug, Galvus and to evaluate the pharmacokinetics after food intake. According to the latest detailed plan, clinical trials will be conducted from January to February next year for a total of 42 healthy adults. The control group is taking 50 mg of Galvus tablet twice a day, and the test group is taking 100 mg of Vildagliptin sustained-release tablet once a day. In the second test group, after taking a high-fat meal, take 100 mg of Vildagliptin sustained-release tablet and compare and analyze the pharmacokinetic characteristics. The original Galvus is 50mg. Alvogen Korea is trying to differentiate itself from domestic competitors by developing Galvus sustained-release tablets. The drug Alvogen develops is a sustained-release multi-layered tablet containing Vilagliptin, which is known to be taken once a day, unlike the original. The original Galvus is 50mg twice daily if needed. On the other hand, Alvogen's product is taken once a day, which seems to improve convenience. Vildaliptin is currently approved by Original Novartis and Generics Ahn-Gook Pharmaceutical. If Alvogen succeeds in commercializing Vildagliptin sustained-release tablets, it will be able to enter the market regardless of Ahn-Gook's right to exclusivity for generic product. This is because the main ingredient is the same, but This is not the case with exclusivity for generic product. However, as Galvus' material patents last until March 4, 2022, they will not be able to enter the market early unless they are neutralized. It is noteworthy which strategy Alvogen will enter the market.
- Company
- Lilly releases first non-reimbursed 'Emgality'
- by Eo, Yun-Ho Dec 13, 2019 06:34am
- Eli Lilly's migraine new drug 'Emgality' was released in Korea. Lilly Korea announced on the 12th that it will release non-reimbursed CGRP-targeted migraines prevention drug, Emgality (Galcanezumab). This drug is a humanized monoclonal antibody that binds to the Calcitonin gene-related peptide (CGRP) molecule which plays a key role in causing migraine symptoms in the brain and blocks binding to receptors. .This is the first drug in Korea .Last year, after being approved for migraine treatment, it recently acquired additional FDA approval for episodic cluster headache treatment .The permission was granted for the EVOLVE-1 and EVOLVE-2 studies in which 1,773 people with migraine headaches (average migraine days 4-14 days per month) participated for 6 months, and chronic migraine patients (average headache days 15 days, migraine days 8 months or more) .The study was based on a REGAIN study involving 1113 people over 3 months .Through two clinical trials for episodic migraine patients, placebo of Emgality-treated patients for migraine treatment compared to baseline (9.2 days for Emgality group, 9.1 days for placebo group) across six months of clinic compared to average monthly migraine incidence for 6 months .Therapeutic benefit was proved .In particular, in the EVOLVE-2 clinical study involving Koreans, the average number of migraine headaches for 6 months in the Emgality group (226 patients) was reduced by 2 days (4.3 days in the Emgality group, 2.3 days in the placebo group) compared to the placebo group (450 patients) .Amgelity-treated patients who had 50% reduction in the number of days of migraine headaches over 6 months were 59% (36% placebo), 75% reduction were 34% (18% in the placebo group), and 100% reduction were 12% (6% in the placebo group) .Min-kyung Chu, neurology professor of Severance hospital, said “Migraine is a pain beyond our imagination that impairs the quality of life of patients, Patients who experience migraines more than four to five days a month can expect to improve their quality of life through preventive care .Emgality's launch is encouraging, with high blood pressure and epilepsy drugs being recommended for preventive treatment .Until now, high blood pressure medications and epilepsy medications have been recommended for preventive treatment” .Meanwhile, commercialization of CGRP-based therapeutics has been ongoing since last year .In addition to Emgality in the United States, drugs such as Aimovig (Erenumab) and Teva's Ajovy (Fremanezumab), which have been jointly developed by Novartis and Amgen, have entered the market.
- Policy
- 'WHO PQ' for 3 domestic vaccines, including Skycellflu
- by Lee, Jeong-Hwan Dec 12, 2019 10:52pm
- Three domestic vaccines have secured international procurement bidding rights, obtaining WHO Prequalification (PQ). SK Bioscience's Sky Cellflu Multi inj, Sky Cellflu inj, and Sky Varicella inj are the main characters. On the 11th, the Ministry of Food and Drug Safety (The Minister, Eui-Kyung Lee) said, "The domestic vaccines passed the WHO PQ, allowing participation in international procurement bidding". WHO PQ is a system for evaluating safety and efficacy for the supply of medicines, including vaccines, to developing countries through international procurement. MFDS has systematically supported WHO certification of domestic vaccines and biosimilar products by establishing a cooperative system with WHO as well as customized consultation services from companies and public-private experts. Specifically, ▲technical consultation on 1: 1 expert consultation team, ▲on-site technical advisory on certificated companies, ▲WHO PQ information sharing seminar, and ▲WHO PQ information book publication. Since 1996, 'Euvax B inj.' is a domestic product that has received WHO Prequalification. There are a total of 16 products by this year. The MFDS said, “We will actively support the activities of companies to enhance the export competitiveness of domestic biopharmaceuticals such as WHO Prequalification, in addition to running customized counseling services, we will continue to publish on-site technical consultations for WHO PQ survey experts and WHO PQ question and answer collections next year”.
- Policy
- Court controversy, the price of Synovian reduction postponed
- by Kim, Jung-Ju Dec 12, 2019 06:31am
- LG Chemicals dissatisfied with the drop in insurance prices, and the price of 3 ml of Synovian (BDDE cross-linked sodium hyaluronate gel), which is fighting a legal battle with the government, is being provisionally maintained. The trial is in progress, and the court has limited the time limit from the date of the sentence to 30 days. The 6th government of the Seoul Administrative Court decided to extend on the 10th of the trial against the company (2019KuHap88095) regarding the decision that the Ministry of Health and Welfare decided to lower the price of this drug in the 'List of Drug Benefits and reimbursed Limits' (Notice 2019-254). Earlier, the Ministry of Health and Welfare decided to lower the price of medicines through the November 28 notice. Afterwards, LG Chemicals filed a lawsuit for unfair drug price cuts, and the court suspended the Ministry of Welfare's action until the first interrogation date. As a result, the price, which was supposed to be lowered to ₩ 477,041, will remain at ₩67,200 as it was until the 30th day from the date of judgment. The Ministry of Health and Welfare explained that the case is currently underway and may change depending on the outcome of the trial in the future, and they will guide you further when it changes“. No.2 is effective as of July 1, 2020, due to the suspension date. As a suspension, ₩67,200 is applied instead of ₩47,041
